Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H25N3S |
Molecular Weight | 339.498 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CCCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CC1
InChI
InChIKey=WEYVCQFUGFRXOM-UHFFFAOYSA-N
InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3
Molecular Formula | C20H25N3S |
Molecular Weight | 339.498 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/16625562Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16625562
Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia. Perazine has being shown to be a potent inhibitor of human CYP1A2. It acts as a dopamine antagonist.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3356 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12523495 |
|||
Target ID: CHEMBL217 Sources: http://www.genome.jp/dbget-bin/www_bget?D01412 |
|||
Target ID: Cytochrome P450 2B, Rattus norvegicus Sources: http://www.ncbi.nlm.nih.gov/pubmed/18048963 |
45.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Taxilan Approved UseTaxilan is used in the treatment of schizophrenia |
PubMed
Title | Date | PubMed |
---|---|---|
[Electroconvulsive therapy in treatment of acute life threatening catatonia in toxic epidermal necrolysis (Lyell syndrome)]. | 1992 May |
|
Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. | 2000 Sep |
|
[Neuroleptic malignant syndrome--case report]. | 2001 |
|
The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. | 2001 Apr |
|
Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. | 2001 Apr |
|
[Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia]. | 2001 Jan-Feb |
|
Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. | 2001 Jul 1 |
|
Examination of iron (III) and hexacyanoferrate (III) ions as reagents for the spectrophotometric determination of promazine and perazine. | 2001 Nov-Dec |
|
Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. | 2001 Nov-Dec |
|
Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. | 2001 Nov-Dec |
|
Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. | 2001 Oct |
|
[Therapy of subclinical (subdiagnostic) syndromes of schizophrenia spectrum]. | 2001 Sep |
|
Perazine for schizophrenia. | 2002 |
|
Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. | 2002 Jul-Aug |
|
Switching to amisulpride due to hepatic complications. | 2002 May |
|
The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. | 2002 Oct |
|
Schizophrenia. | 2003 Dec |
|
Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. | 2003 Mar-Apr |
|
The AMUP study for drug surveillance in psychiatry - a summary of inpatient data. | 2004 Mar |
|
Acute psychosis with a mediastinal carcinoma metastasis. | 2005 Jan |
|
Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. | 2005 Jun |
|
Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography. | 2005 Nov-Dec |
|
Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. | 2005 Nov-Dec |
|
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. | 2006 Aug |
|
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. | 2006 Mar |
|
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | 2006 Oct 20 |
|
[Ischemic colitis without atherosclerosis?]. | 2007 Mar 30 |
|
The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment. | 2007 Sep-Oct |
|
Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE). | 2008 |
|
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008 Dec 22 |
|
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | 2008 Feb |
|
Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. | 2008 Jun |
|
[Application of liquid chromatography coupled with mass spectrometry (LC/MS) to determine antidepressants in blood samples]. | 2008 Oct-Dec |
|
Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. | 2009 Sep 16 |
|
Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study. | 2009 Sep-Oct |
|
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes. | 2010 Mar |
|
Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. | 2010 Oct 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11869638
Curator's Comment: In acutely ill and severely disturbed patients 50 mg perazine at time-intervals of 30 minutes can be administered intramuscularly
The customary dose range recommended for this antipsychotic under in-patient conditions is 75-600 mg/day (maximum 1000 mg/day).
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19904008
About 80% of basal human CYP1A2 activity was reduced by the therapeutic concentrations of perazine (5-10 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:23 UTC 2023
by
admin
on
Fri Dec 15 16:18:23 UTC 2023
|
Record UNII |
8915147A2B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05AB10
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
||
|
WHO-ATC |
N05AB10
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
||
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8042
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | RxNorm | ||
|
84-97-9
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
Perazine
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
C81093
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
8915147A2B
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
100000079987
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
2100
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
4744
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
DTXSID6048628
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
DB12710
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
CHEMBL1697766
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
D010464
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
SUB14811MIG
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | |||
|
m8535
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY | Merck Index | ||
|
201-578-9
Created by
admin on Fri Dec 15 16:18:23 UTC 2023 , Edited by admin on Fri Dec 15 16:18:23 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |